Zai Lab (ADR) (ZLAB)
Develops and commercializes therapies through partnerships and internal research.
Something off on this page? Send us feedback.
Develops and commercializes therapies across oncology, immunology, neuroscience, and infectious disease. Its Greater China portfolio combines in-licensed assets and global-biopharma partnerships with internal research.
Discovers, develops, and commercializes therapies in oncology, immunology, neuroscience, and infectious disease, serving patients in Greater China while operating across China and the United States. Its model combines clinical development, commercial infrastructure, and research capabilities.
The commercial portfolio is built through in-licensed assets and partnerships with global biopharma companies, supported by clinical-trial and commercial infrastructure in China. ZEJULA's China rights, first licensed from Tesaro, illustrate this approach.
Internal discovery programs add a global R&D component beside regional development and commercialization work. License-and-collaboration agreements can require product purchases, royalties, and milestone payments.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jan 7, 2026 | UBS | Target | Target: — | Target: $35 |
| Mar 3, 2025 | B of A Securities | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $617.5M · Total debt $254.6M · Total assets $1.07B · Shareholders' equity $607.0M
- Revenue
- $106.3M
- Operating income
- −$76.5M
- Net income
- −$50.8M
No dividends on record.
| Institutions | ≥ 29.44% | 43.10M ADS | |
|---|---|---|---|
| 97 holders · as of Jun 30, 2026 | |||
| Insiders | 1.72% | 2.52M ADS | |
| 14 holders · as of Aug 21, 2026 | |||
| Other | ≤ 68.84% | 100.77M ADS | |
| remainder | |||
146.39M ADS (1 ADS = 10 ordinary shares) as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (146.39M in the company's Sep 22, 2026 report, 112.92M elsewhere); stakes use the report.
Institutional filings for 9688 (768% of the company) are not on file here, so the institutional figure is a floor.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
RTW Investments, LPInstitution | 4.49% | 6.57M ADS | as of Jun 30, 2026 |
TCG Crossover Management, LLCInstitution | 4.19% | 6.14M ADS | as of Jun 30, 2026 |
Ra Capital Management, L.P.Institution | 3.92% | 5.74M ADS | as of Jun 30, 2026 |
Adar1 Capital Management, LLCInstitution | 2.30% | 3.37M ADS | as of Jun 30, 2026 |
FMR LLCInstitution | 1.92% | 2.82M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Yajing Chen | officer: Chief Financial Officer | −260 | $27.00 |
| Aug 12, 2026 | William Lis | director | −8,506 | $25.00 |
| Aug 11, 2026 | Yajing Chen | officer: Chief Financial Officer | −619 | $25.00 |
| Jul 1, 2026 | Richard Gaynor | director | +1,736 | $19.05 |
| Jun 30, 2026 | Ying Du | director, officer: Chairperson & CEO | −7,026 | $18.53 |
- BeOne Medicines (ADR)
Global oncology portfolio with a substantial China commercial presence
- HUTCHMED (ADR)
China-focused oncology portfolio and commercialization infrastructure
- AstraZeneca (ADR)
Global oncology franchise with China-market scale and PARP overlap
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Zai Lab (ADR) | $26.91 | +1.82% | $2.98B | — | — | 6.6 | −3.3% |
| BeOne Medicines (ADR) | $363.58 | −0.57% | $39.07B | 5.1 | 46.1 | 6.4 | +29.6% |
| HUTCHMED (ADR) | $14.15 | −2.31% | $2.53B | 140.6 | — | 4.6 | +0.2% |
| AstraZeneca (ADR) | $168.49 | +0.23% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Median | 25.2 | 31.0 | 4.6 | +6.4% |